Working with TipRanks
Follow Us
Stocks
ETFs
Options
Crypto
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novabay Pharmaceuticals (NBY)
NYSE MKT:NBY
NovaBay Pharma (NBY) Stock Price & Analysis
517 Followers
NBY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.28 - $2.66
Previous Close$0.3
Volume171.90K
Average Volume (3M)1.15M
Market Cap
$1.96M
Enterprise Value$1.49M
Total Cash (Recent Filing)$3.47M
Total Debt (Recent Filing)$3.00M
Price to Earnings (P/E)>-0.1
Beta1.34
Next Earnings
Mar 21, 2024EPS Estimate
-$0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.83
Shares Outstanding6,529,302
10 Day Avg. Volume79,410
30 Day Avg. Volume1,148,757
Standard Deviation0.48
R-Squared0.10
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.45
Price to Sales (P/S)3.50
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.09
Enterprise Value/Gross Profit-0.25
Enterprise Value/Ebitda-0.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NovaBay Pharma News
Pre-EarningsIs NBY a Buy, Before Earnings?
Pre-EarningsIs NBY a Buy, Before Earnings?
NBY FAQ
What was Novabay Pharmaceuticals’s price range in the past 12 months?
Novabay Pharmaceuticals lowest stock price was $0.28 and its highest was $2.66 in the past 12 months.
What is Novabay Pharmaceuticals’s market cap?
Currently, no data Available
When is Novabay Pharmaceuticals’s upcoming earnings report date?
Novabay Pharmaceuticals’s upcoming earnings report date is Mar 21, 2024 which is in 110 days.
How were Novabay Pharmaceuticals’s earnings last quarter?
Novabay Pharmaceuticals released its earnings results on Nov 09, 2023. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.405 by $0.035.
Is Novabay Pharmaceuticals overvalued?
According to Wall Street analysts Novabay Pharmaceuticals’s price is currently Overvalued.
Does Novabay Pharmaceuticals pay dividends?
Novabay Pharmaceuticals does not currently pay dividends.
What is Novabay Pharmaceuticals’s EPS estimate?
Novabay Pharmaceuticals’s EPS estimate is -$0.3.
How many shares outstanding does Novabay Pharmaceuticals have?
Novabay Pharmaceuticals has 6,529,302 shares outstanding.
What happened to Novabay Pharmaceuticals’s price movement after its last earnings report?
Novabay Pharmaceuticals reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.405. Following the earnings report the stock price went down -8.571%.
Which hedge fund is a major shareholder of Novabay Pharmaceuticals?
Currently, no hedge funds are holding shares in NBY
---
NovaBay Pharma Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.78%
12-Months-Change
Fundamentals
Return on Equity
-131.96%
Trailing 12-Months
Asset Growth
-42.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Novabay Pharmaceuticals
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing products for the eye care market. Its products include Avenova, NeutroPhase, and CelleRx. The company was founded by Ramin Najafi on January 19, 2000 and is headquartered in Emeryville, CA.
---
Top 5 ETFs holding NBY
iShares Core S&P Total U.S. Stock Market ETF
$6.01
Up to five ETFs with an Outperform Smart Score that hold NBY. The ETFs are listed according to market value of NBY within the ETF
---